AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
moxidectin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiparasitics, ivermectin derivatives | 5286 | 113507-06-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism by which moxidectin exhibits its effect against O. volvulus is not known. Studies with other nematodes suggest that moxidectin binds to glutamate-gated chloride channels (GluCl), gamma-aminobutyric acid (GABA) receptors and/or ATP-binding cassette (ABC) transporters. This leads to increased permeability, influx of chloride ions, hyperpolarization and muscle paralysis. Additionally, there is a reduction in motility of all stages of the parasite, excretion of immunomodulatory proteins, and the fertility of both male and female adult worms.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 18 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 13, 2018 | FDA | MDGH |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02CX03 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Other antinematodals |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D007306 | Insecticides |
| MeSH PA | D010575 | Pesticides |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection by Onchocerca volvulus | indication | 38539003 | DOID:11678 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Prevention of heartworm disease caused by Dirofilaria immitis | Indication |
| Cats | Ear mite infestations with Otodectes cynotis | Indication |
| Cats | Treatment and control of intestinal roundworms, Toxocara cati | Indication |
| Cats | Treatment and control of hookworms, Ancylostoma tubaeforme | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Ostertagia ostertagi (adult and L4, including inhibited larvae) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Haemonchus placei (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Trichostrongylus axei (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, T colubriformis (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Cooperia oncophora (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, C pectinata (adult) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, C punctata (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, C spatulata (adult) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, C surnabada (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Bunostomum phlebotomum (adult) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Oesophagostomum radiatum (adult and L4) | Indication |
| Cattle | Treatment and control of gastrointestinal roundworms, Nematodirus helvetianus (adult and L4) | Indication |
| Cattle | Treatment and control of lungworms, Dictyocaulus viviparus, (adult and L4) | Indication |
| Cattle | Treatment and control of grubs, Hypoderma bovis | Indication |
| Cattle | Treatment and control of mites, Chorioptes bovis | Indication |
| Cattle | Treatment and control of mites, Psoroptes ovis (P communis var bovis)) | Indication |
| Cattle | Treatment and control of lice, Linognathus vituli | Indication |
| Cattle | Treatment and control of lice, Haematopinus eurysternus | Indication |
| Cattle | Treatment and control of lice, Solenopotes capillatus | Indication |
| Cattle | Treatment and control of lice, Bovicola bovis | Indication |
| Cattle | Treatment and control of horn flies, Haematobia irritans | Indication |
| Cattle | Protection (14 days) from reinfection with H placei | Indication |
| Cattle | Protection (28 days) from reinfection with O radiatum | Indication |
| Cattle | Protection (42 days) from reinfection with D viviparus | Indication |
| Cattle | Protection (28 days) from reinfection with O ostertagi | Indication |
| Cattle | Treatment and control of grubs, H lineatum | Indication |
| Dogs | Treatment of infections with hookworm, Ancylostoma caninum | Indication |
| Dogs | Prevents infection by heartworm Dirofilaria immitis | Indication |
| Dogs | Treatment of infections with hookworm, Unicinaria stenocephala | Indication |
| Ferrets | Prevention of heartworm disease caused by Dirofilaria immitis | Indication |
| Horses | Treatment and control of Large Strongyles, Strongylus vulgaris (adults and L4 / L5 arterial stages) | Indication |
| Horses | Treatment and control of Large Strongyles, Strongylus edentatus (adults and tissue stages) | Indication |
| Horses | Treatment and control of Large Strongyles, Triodontophorus brevicauda (adults) | Indication |
| Horses | Treatment and control of Large Strongyles,Triodontophorus serratus (adults) | Indication |
| Horses | Treatment and control of Small Strongyles, Cyathostomum catinatum | Indication |
| Horses | Treatment and control of Small Strongyles, Cyathostomum pateratum | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicostephanus calicatus | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicostephanus goldi | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicostephanus longibursatus | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicostephanus minutus | Indication |
| Horses | Treatment and control of Small Strongyles, including Cylicocyclus insigne | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicocyclus leptostomum | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicocyclus nassatus | Indication |
| Horses | Treatment and control of Small Strongyles, Cylicocyclus radiatusm | Indication |
| Horses | Treatment and control of Small Strongyles, Coronocyclus coronatus | Indication |
| Horses | Treatment and control of Small Strongyles, Coronocyclus labiatus | Indication |
| Horses | Treatment and control of Small Strongyles, Coronocyclus labratus | Indication |
| Horses | Treatment and control of Small Strongyles, Gyalocephalus capitatus | Indication |
| Horses | Treatment and control of Small Strongyles, Petrovinema poculatus | Indication |
| Horses | Treatment and control of Small Strongyles, undifferentiated lumenal larvae | Indication |
| Horses | Treatment and control of Encysted cyathostomes (Late L3 and L4, mucosal cyathostome larvae) | Indication |
| Horses | Treatment and control of Ascarids Parascaris equorum (adults and L4 larval stages) | Indication |
| Horses | Treatment and control of Pinworms, Oxyuris equi (adults and L4 larval stages) | Indication |
| Horses | Treatment and control of Hairworms, Trichostrongylus axei (adults) | Indication |
| Horses | Treatment and control of Large-mouth stomach worms, Habronema muscae (adults) | Indication |
| Horses | Treatment and control of Stomach bots, Gasterophilus intestinalis (2nd and 3rd instars) | Indication |
| Horses | Treatment and control of Gasterophilus nasalis (3rd instars) | Indication |
| Horses | Suppresses strongyle egg production | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of Haemonchus contortus | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of Teladorsagia circumcincta | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of T trifurcate | Indication |
| Sheep | Treatment and control of the gastrointestinal roundworms, Trichostrongylus axei (Adults and fourth-stage larvae) | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of T colubriformis | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of T vitrines | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of Cooperia curticei | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of C oncophora | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of Oesophagostomum columbianum | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of O venulosum | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of Nematodirus battus | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of N filicollis | Indication |
| Sheep | Treatment and control of the adult and L4 larval stages of N spathiger | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| ProHeart | Zoetis Inc. | 1 |
| Quest Gel | Zoetis Inc. | 1 |
| Cydectin (moxidectin) Pour-On for Beef and Dairy Cattle | Elanco US Inc. | 1 |
| ProHeart 6 | Zoetis Inc. | 1 |
| Quest Plus Gel | Zoetis Inc. | 2 |
| Cydectin | Elanco US Inc. | 1 |
| Cydectin Oral Drench for Sheep | Elanco US Inc. | 1 |
| Advantage Multi for Dogs | Elanco US Inc. | 2 |
| Advantage Multi for Cats | Elanco US Inc. | 2 |
| CORAXIS | Elanco US Inc. | 1 |
| BRAVECTO PLUS | Intervet Inc. | 2 |
| ProHeart 12 | Zoetis Inc. | 1 |
| Simparica Trio | Zoetis Inc. | 3 |
| IMOXI Topical Solution for Dogs | Vetoquinol USA Inc. | 2 |
| IMOXI Topical Solution for Cats | Vetoquinol USA Inc. | 2 |
| PARASEDGE Multi for Dogs | Chanelle Pharmaceuticals Manufacturing Ltd. | 2 |
| PARASEDGE Multi for Cats | Chanelle Pharmaceuticals Manufacturing Ltd. | 2 |
| Barrier for cats | Aurora Pharmaceutical Inc. | 2 |
| Midamox for Dogs | Norbrook Laboratories, Ltd. | 2 |
| Barrier for dogs | Aurora Pharmaceutical Inc. | 2 |
| Midamox for Cats | Norbrook Laboratories, Ltd. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.24 | acidic |
| pKa2 | 13.33 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 2MG | MOXIDECTIN | MDGH | N210867 | June 13, 2018 | RX | TABLET | ORAL | Feb. 7, 2028 | NEW PATIENT POPULATION |
| 2MG | MOXIDECTIN | MDGH | N210867 | June 13, 2018 | RX | TABLET | ORAL | Feb. 7, 2032 | TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PEDIATRIC PATIENTS AGED 4 TO LESS THAN 12 YEARS AND WEIGHING AT LEAST 13 KG |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutamate-gated chloride channel | Ion channel | INHIBITOR | UNKNOWN | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| NGU5H31YO9 | UNII |
| C0163557 | UMLSCUI |
| CHEBI:183811 | CHEBI |
| CHEMBL2104415 | ChEMBL_ID |
| 9832912 | PUBCHEM_CID |
| DB11431 | DRUGBANK_ID |
| D05084 | KEGG_DRUG |
| 6400 | INN_ID |
| C027837 | MESH_SUPPLEMENTAL_RECORD_UI |
| 781257003 | SNOMEDCT_US |
| 781277005 | SNOMEDCT_US |
| 017593 | NDDF |
| 1047072 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Moxidectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71705-050 | TABLET | 2 mg | ORAL | NDA | 29 sections |
| Moxidectin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71705-050 | TABLET | 2 mg | ORAL | NDA | 29 sections |